Pairing GLP-1 Drugs with a Digital Health App Boosts Weight Loss by 3 Percentage Points in 58,000 Users | Research

The takeaway

Among nearly 58,000 UK users of semaglutide or tirzepatide, those who actively engaged with a digital weight management app lost 9% vs 5.9% at 3 months and 11.5% vs 8% at 5 months — with tirzepatide users achieving 13.9% loss.

9% vs 5.9% weight loss at 3 months
Among 57,975 GLP-1 drug users, those actively engaging with a digital health app lost 53% more weight than non-engaged users — a large effect (Cohen d=0.89) demonstrating that behavioral support meaningfully amplifies medication effectiveness.

What the researchers found

Of 57,975 participants, 54.2% were classified as engaged and 45.8% as non-engaged with the digital platform. At month 3: engaged lost 9% vs non-engaged 5.9% (P<0.001, Cohen d=0.89 — large effect). At month 5: engaged lost 11.53% vs non-engaged 8% (P<0.001, Cohen d=0.56 — moderate effect). Tirzepatide users achieved greater weight loss than semaglutide users at month 5 (13.9% vs 9.5%, P<0.001). Engaged participants were significantly more likely to achieve ≥5%, ≥10%, and ≥15% weight loss thresholds at all time points.

Why it matters

With millions now taking GLP-1 drugs, optimizing their effectiveness is a major healthcare priority. This study — one of the largest real-world GLP-1 datasets published — demonstrates that behavioral support through digital platforms meaningfully amplifies drug effectiveness. A 3-percentage-point improvement in weight loss translates to clinically significant additional health benefits. This supports pairing medication with structured behavioral programs rather than prescribing drugs alone.

How the study worked

Retrospective cohort service evaluation using data from the Voy weight loss digital health platform (UK, February 2023-August 2024). Included 57,975 adults (BMI ≥30 or ≥27.5 with comorbidities) initiating semaglutide or tirzepatide. Engagement defined by coaching session attendance, app usage frequency, and weight tracking regularity. Weight loss assessed over 5 months. Statistics: chi-square tests, independent t-tests, Kaplan-Meier survival analysis, Cohen d effect sizes.

What this study cannot tell us

Retrospective observational design — engaged users may differ systematically from non-engaged users in motivation, socioeconomic status, and baseline health. Selection bias is likely, as more motivated individuals may both engage more and lose more weight regardless of the app. The 5-month follow-up is relatively short for obesity management. Data came from a commercial digital platform, introducing potential reporting and measurement biases. The specific components of engagement (coaching vs. tracking vs. app use) weren't separately analyzed for their contributions. UK-specific healthcare and cultural context may limit generalizability.

How to read the evidence

This is a very large retrospective cohort study (n=57,975) with robust statistical analysis including effect sizes. However, the observational design cannot establish causation — engaged users may inherently be more motivated. The commercial platform setting may introduce biases. A randomized controlled trial would be needed to confirm the causal effect of digital engagement.

When this study was published

Published in 2025 in JMIR with data through August 2024, this is one of the largest and most current real-world studies of GLP-1 drug outcomes combined with digital health support.

The bigger picture

The obesity treatment paradigm is shifting from 'just prescribe a drug' to integrated approaches combining pharmacotherapy with behavioral support. This study provides the largest evidence base to date supporting this combination. As digital health platforms scale and GLP-1 prescriptions surge, integrating the two could become standard of care — potentially improving outcomes for millions of people at minimal incremental cost.

Questions still open

Does digital engagement improve long-term weight maintenance after GLP-1 drugs are discontinued?
Which specific digital engagement components (coaching, tracking, community features) drive the weight loss improvement?
Would a randomized trial confirm that digital engagement causes better outcomes rather than merely correlating with them?

Common questions

Do weight loss apps actually help when taking GLP-1 medications?

Yes, according to this study of nearly 58,000 people. Those who actively used a digital weight management app while taking semaglutide or tirzepatide lost significantly more weight — 9% versus 5.9% at 3 months. The effect was large and consistent across time points, suggesting that combining medication with structured behavioral support through an app produces better results than medication alone.

Which works better for weight loss — semaglutide or tirzepatide?

In this large real-world study, tirzepatide users lost more weight than semaglutide users at 5 months (13.9% vs 9.5%). This is consistent with clinical trial data showing tirzepatide's dual GIP/GLP-1 mechanism produces greater weight loss. However, both drugs are effective, and the choice may depend on individual factors, cost, and insurance coverage.

Read the original research

Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study.

Journal of medical Internet research, 27, e69466

View on PubMed ↗Publisher’s paper ↗

Citation

Johnson, Hans; Huang, David; Liu, Vivian; Ammouri, Mahmoud Al; Jacobs, Christopher; El-Osta, Austen. (2025). Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study.. Journal of medical Internet research, 27, e69466. https://doi.org/10.2196/69466